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is a registered trademark. for fully informed policy decisions. Moreover, there were problems in the implementation of the new procedures that resulted in the omission of some major policy items.
Statement of Peter Reuter

Background
Let me start with a bit of background. Drug budgets have been a staple of the drug policy debate since 1973. By the time that ONDCP began operating in 1989, the methodology underlying the drug budget was well-established. Specifically, the budget was divided between demand-side programs (prevention and treatment) and supply-side programs (domestic and international enforcement), a division that had already provided a major battleground for public debate throughout the 1980s. Congress initially required statutorily that ONDCP report the division of expenditures between demand and supply reduction; while it continues to report this division, it gives the division less emphasis.
Federal agencies were given guidelines to produce defensible estimates of how much they were spending on drug control under different program categories to reduce U.S.
drug problems. As a result, the length of the budget document accompanying the release of the annual National Drug Control Strategy came to exceed the length of the strategy itself.
The drug budget served a number of purposes. For many readers, it provided an important description of drug policy. That policy, of course, is the set of programs and laws governing drug use and distribution. It has many dimensions, such as the number of persons in treatment, the share of school children age 10-14 receiving drug prevention programs, and the number of persons prosecuted for selling drugs. Much of that policy is the result not of federal decisions but of the independent decisions of state and local governments. Still, the federal government has been an important actor in most aspects of policy. In short, the federal budget, giving both total federal expenditures and the composition of such expenditures, was one important part of the description of national drug policy.
In addition to serving this descriptive role, the drug budget served more functional goals as well. In the absence of much evaluation of individual programs, the drug budget was often interpreted as providing a broad sense of how well the federal government was doing in its drug control decisions. For example, if interdiction expenditures were rising and more drugs were flowing across the border at lower prices, then a question might be raised about whether the interdiction program was being effectively operated. In the 1990s, ONDCP constructed an elaborate performance measurement system linked to the budget. A recent UK exercise provided definitions and examples: "Proactive budget and spend is that which is aimed at tackling the causes of the drug problem. Examples include supply reduction, prevention and anti-drugs education. Treatment is also proactive although, by definition, reacting to an existing problem rather than preventing it at source." "Reactive budget and spend is that which results from the drugs problem but which, of itself, does little, if anything to solve it or address the underlying causes.
Examples include most (but by no means all) police enforcement costs, prison accommodation and court costs." For accountability purposes, agencies were required to focus on the proactive items in this exercise.
However, the resulting "proactive" document is only one of two separate budgeting exercises that the British government undertakes. Indeed, to my knowledge, the proactive document has never been published, and it deals with much less than half of total drug control spending. The British government also occasionally publishes a comprehensive budget that includes "reactive" programs. This broader budget breaks down all targeted expenditures and is very reminiscent of the approach developed by Agencies with a small drug-related workload or with programs addressing a wide range of issues were removed from the budget unless funding could be reorganized and displayed to show drug funding in discreet "decision units."
Done properly, these two changes would allow ONDCP to focus its attention on programs that specifically target drug use rather than its consequences and that are not buried inside much larger programs that have much broader goals. That seems a reasonable enough exercise for the agency's own purposes.
However, there are two problems. First, as implemented, the new budget does not seem to meet the criteria laid out for it. And second, and perhaps more important, there is a need for a more comprehensive budget for broader public purposes.
Problems with Implementation
The major difference between the two budgets (as shown by the comparisons Incarceration is what makes investigation, which is included in the budget, effective as a method for deterring drug dealers. Investigation does impose other costs on the drug distribution system through seizure of drugs and assets. However, the bulk of the costs that federal enforcement imposes on the drug distribution system result from incarceration rather than from these other penalties. Thus, if one seeks to estimate the total costs of federal efforts to reduce drug use, then both prosecution and incarceration should be included, not just prosecution, as is now the case. 
The Need for a Comprehensive Budget for Broader Public Purposes
The above argument shows that as implemented, the new budget does not seem to meet the criteria laid out for it. But even if there were no implementation problem, there is still a need for a comprehensive budget to meet broader public purposes. Also, ONDCP notes that many costs not included in the budget are included in More complete estimates are provided, but these estimates appear in an essentially academic publication, one that has a long lag time. In particular, the ONDCP web site currently contains a 2001 report presenting estimates through 1998 (with projections through 2001). As an academic and researcher myself, I suggest that this kind of delay is almost an inevitable consequence of the contract research process.
Recommendations
The reformulated ONDCP budget concept, if properly implemented, can serve a useful purpose. It focuses the agency on what it can influence. However, that budget document needs to be supplemented by the recreation of the old, more comprehensive budget, which can inform the broader debate about drug policy. That will allow the public and Congress to better understand the costs of current policy and help them make more informed decisions about issues that are important but lie outside of ONDCP's jurisdiction.
It would be even more useful if there were also regular estimates of expenditures by state and local governments. The only study that estimated such expenditures (which came out in 1991) showed total expenditures that were almost as much as those of the federal government. It is plausible, given the growth in the number of drug offenders in state prison, that this remains true, but that is very speculative. Nonetheless, it is clear that state and local governments spend many billions of dollars on drug control and that the federal budget is an inadequate characterization of either the level or the composition of U.S. drug policy expenditures. Estimating these figures would be a complex but feasible research undertaking. If Congress wishes to have a full understanding of drug policy in the nation and the role that federal programs play, it needs this broader set of figures.
I am happy to answer questions.
